Amarillo Biosciences to Hold Annual Meeting on June 22, 2006
Dr. Manfred Beilharz will be traveling from Perth, Australia, where he is the Head of the Nobel Prize winning Department of Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences, the University of Western Australia. Dr. Beilharz will discuss his research with oral interferon and influenza, including his recent mouse study in which oral interferon protected mice given a lethal influenza challenge. Dr. Beilharz will also discuss his proposed human influenza study and published reports on the efficacy and safety of oral interferon in relapsing-remitting multiple sclerosis.
Dr. Lorenz Lutherer, Professor of Physiology and Internal Medicine at Texas Tech University Health Sciences Center, will discuss his research with oral interferon in idiopathic pulmonary fibrosis (IPF) and his recommendations for the Company's next IPF study.
Shareholders will vote to elect six directors to Board of Directors, including two new directors. The two new nominees on the slate for election to the Company's Board of Directors are:
Mr. Thomas D'Alonzo is a seasoned executive with experience in all major facets of pharmaceutical operations: sales and marketing, manufacturing, quality assurance, finance and licensing, and strategic planning. Mr. D'Alonzo served as President of Pharmaceutical Product Development, Inc., a multi-national clinical research organization with 3,000 employees operating in 14 countries and generating $300 million in revenues from analytical labs and Phase I, II, III and IV clinical trials. Previously, Mr. D'Alonzo was President of Genevec, Inc., a gene therapy biotech company with basic research programs in adenovirus and herpes virus vectors for gene delivery to cells. Before that, Mr. D'Alonzo was President of Glaxo, Inc., the U.S. unit of what is now Glaxo SmithKline plc.
Mr. Thomas Ulie, a Chartered Financial Analyst, has been in the investment field for more than 30 years, and is currently CEO of First Island Capital, Inc., a West Coast-based NASD broker-dealer firm. Mr. Ulie also serves as a director of a number of medical companies and has wide ranging experience in the investment community, having worked in investment banking, money management and research. Prior to First Island Capital, Mr. Ulie was a Senior Managing Director for the Stanford Company, a NYSE member firm. Prior to that, Mr. Ulie was an Associate Director of Bear Stearns & Co.
About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 15.5% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 22-year history, ABI has invested nearly $37 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.
Herpes Treatment
|
